Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.

Recent evidence suggests that pancreatic cancer and other solid tumors contain a subset of tumorigenic cells capable of extensive self-renewal that contribute to metastasis and treatment resistance. Sorafenib (SO) is a promising new multikinase inhibitor for treatment of advanced kidney and liver cancers. We report here targeting of pancreatic cancer stem cells (CSC) by SO and the development of a strategy to enhance this effect. Although SO administration diminished clonogenicity, spheroid formation, aldehyde dehydrogenase 1 (ALDH1) activity, growth on immunodeficient mice, proliferation, and angiogenesis and induced apoptosis, we observed SO-induced activation of NF-kappaB associated with survival and regrowth of spheroids. For enhanced elimination of CSC characteristics by SO, we cotreated cells with sulforaphane (SF). This broccoli isothiocyanate was recently described to eliminate pancreatic CSCs by downregulation of NF-kappaB activity without inducing toxic side effects. On combination treatment, SF completely eradicated SO-induced NF-kappaB binding, which was associated with abrogated clonogenicity, spheroid formation, ALDH1 activity, migratory capacity, and induction of apoptosis. In vivo, combination therapy reduced the tumor size in a synergistic manner. This was due to induction of apoptosis, inhibition of proliferation and angiogenesis, and downregulation of SO-induced expression of proteins involved in epithelial-mesenchymal transition. Our data suggest that SF may be suited to increase targeting of CSCs by SO.

[1]  M. Büchler,et al.  Dietary constituents of broccoli and other cruciferous vegetables: implications for prevention and therapy of cancer. , 2010, Cancer treatment reviews.

[2]  H. Broxterman,et al.  CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients , 2009, British Journal of Cancer.

[3]  Justin C. Grindley,et al.  Tumour-initiating cells: challenges and opportunities for anticancer drug discovery , 2009, Nature Reviews Drug Discovery.

[4]  D. Hedley,et al.  Cancer stem cells, hypoxia and metastasis. , 2009, Seminars in radiation oncology.

[5]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[6]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[7]  P. Altevogt,et al.  Sulforaphane targets pancreatic tumour-initiating cells by NF-κB-induced antiapoptotic signalling , 2008, Gut.

[8]  H. Friess,et al.  VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma , 2008, British Journal of Cancer.

[9]  H. Friess,et al.  Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer , 2008, Cancer Gene Therapy.

[10]  A. Apel,et al.  Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. , 2008, Cancer research.

[11]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[12]  M. Mimeault,et al.  Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers , 2007, Journal of cellular and molecular medicine.

[13]  Jeffrey N. Myers,et al.  Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice , 2007, Molecular Cancer Therapeutics.

[14]  O. Ammerpohl,et al.  Detection of tumor stem cell markers in pancreatic carcinoma cell lines. , 2007, Hepatobiliary & pancreatic diseases international : HBPD INT.

[15]  S. Badve,et al.  NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 , 2007, Oncogene.

[16]  S. Wilhelm,et al.  Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.

[17]  D. Strumberg,et al.  Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  H. Friess,et al.  Corticosteroid co-treatment induces resistance to chemotherapy in surgical resections, xenografts and established cell lines of pancreatic cancer , 2006, BMC Cancer.

[19]  M. Santoro,et al.  BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.

[20]  B. Petersen,et al.  AUTOIMMUNE PANCREATITIS: DIAGNOSIS USING HISTOLOGY, IMAGING, SEROLOGY, OTHER ORGAN INVOLVEMENT AND RESPONSE TO STEROIDS , 2005 .

[21]  D. Strumberg,et al.  Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. , 2005, Clinical colorectal cancer.

[22]  S. Pandol,et al.  Cell Death Pathways in Pancreatitis and Pancreatic Cancer , 2004, Pancreatology.

[23]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[24]  M. Piccart,et al.  381 A phase I study of BAY 43-90006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced solid tumors , 2004 .

[25]  Andreas Sommer,et al.  NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression , 2004 .

[26]  J. Massagué,et al.  Epithelial-Mesenchymal Transitions Twist in Development and Metastasis , 2004, Cell.

[27]  K. Flaherty,et al.  Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Piccart,et al.  A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Chandler,et al.  Increased expression of NF-κB subunits in human pancreatic cancer cells1,2 ☆ , 2004 .

[30]  Richard J. Jones,et al.  Cancer stem cells: are we missing the target? , 2004, Journal of the National Cancer Institute.

[31]  E. Lin,et al.  NF‐κB activity blockade impairs the angiogenic potential of human pancreatic cancer cells , 2004 .

[32]  Harald J. Maier,et al.  Critical Role of RelB Serine 368 for Dimerization and p100 Stabilization* , 2003, Journal of Biological Chemistry.

[33]  A. Arlt,et al.  Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death , 2003, Oncogene.

[34]  J. Koziol,et al.  A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. , 1981, Biometrics.

[35]  M. Piccart-Gebhart,et al.  A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors , 2004 .